What is HC Wainwright’s Forecast for ACAD FY2028 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at HC Wainwright increased their FY2028 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Monday, December 15th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will earn $3.12 per share for the year, up from their previous forecast of $2.74. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2029 earnings at $3.27 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.28. The firm had revenue of $278.63 million during the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.ACADIA Pharmaceuticals’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS.

Other equities research analysts have also recently issued research reports about the stock. Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 11th. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. cut their target price on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft set a $29.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $29.95.

ACADIA Pharmaceuticals Trading Up 0.5%

Shares of ACAD opened at $26.93 on Thursday. The firm has a market cap of $4.56 billion, a P/E ratio of 17.37, a PEG ratio of 7.26 and a beta of 0.67. ACADIA Pharmaceuticals has a 12 month low of $13.40 and a 12 month high of $27.73. The stock’s 50 day moving average is $23.59 and its two-hundred day moving average is $23.32.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $283,000. Danske Bank A S purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at about $1,002,000. CANADA LIFE ASSURANCE Co increased its position in ACADIA Pharmaceuticals by 1.8% during the third quarter. CANADA LIFE ASSURANCE Co now owns 123,246 shares of the biopharmaceutical company’s stock worth $2,628,000 after purchasing an additional 2,131 shares during the last quarter. Virtus Advisers LLC raised its stake in ACADIA Pharmaceuticals by 1,283.1% during the third quarter. Virtus Advisers LLC now owns 42,974 shares of the biopharmaceutical company’s stock worth $917,000 after purchasing an additional 39,867 shares during the period. Finally, Verition Fund Management LLC raised its stake in ACADIA Pharmaceuticals by 63.0% during the third quarter. Verition Fund Management LLC now owns 18,749 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 7,244 shares during the period. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director James M. Daly sold 30,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $22.37, for a total transaction of $671,100.00. Following the completion of the sale, the director owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. This represents a 88.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Kihara sold 4,084 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $96,749.96. Following the completion of the sale, the insider owned 25,058 shares of the company’s stock, valued at approximately $593,624.02. The trade was a 14.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 44,346 shares of company stock worth $1,010,957. 26.50% of the stock is owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.